Mechanisms of transformation by the BCR-ABL oncogene: New perspectives in the post-imatinib era

Leukemia Research

Volumn 28, Issue SUPPL. 1, 2004, Pages 21-28

  Van Etten, Richard A ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Chronic myelogenous leukemia; Gleevec; Imatinib mesylate; Oncogene; Tyronsine kinase

Indexed keywords

6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; GENE PRODUCT; IMATINIB; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME CONFORMATION; GENE FUNCTION; GENE TARGETING; GENETIC REGULATION; HUMAN; LEUKEMOGENESIS; ONCOGENE; ONCOGENE BCR ABL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

EID: 1342300625     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.10.005     Document Type: Article

References (63)

1. Van Etten R.A., Debnath J., Zhou H., Casasnovas J.M. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro. Oncogene. 10:1995;1977-1988.
2. Barila D., Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18:1998;280-282.
3. Brasher B.B., Roumiantsev S., Van Etten R.A. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain. Oncogene. 20:2001;7744-7752.
4. Brasher B.B., Van Etten R.A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 275:2000;35631-35637.
5. Plattner R., Kadlec L., DeMali K.A., Kazlauskas A., Pendergast A.M. c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev. 13:1999;2400-2411.
6. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science. 289:2000;1938-1942.
7. Xu W., Harrison S.C., Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature. 385:1997;595-602.
8. Sicheri F., Moarefi I., Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature. 385:1997;602-609.
9. Yamaguchi H., Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 384:1996;484-489.
10. Roumiantsev S., Shah N.P., Gorre M.E., Nicoll J., Brasher B.B., Sawyers C.L.et al. Clinical resistance to the kinase inhibitor STI-571 in CML by mutation of Tyr253 in the Abl kinase domain P-loop. Proc. Natl. Acad. Sci. USA. 99:2002;10700-10705.
11. Buchdunger E., Zimmermann J., Mett H., Meyer T., Müller M., Druker B.J.et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 56:1996;100-104.
12. Harrison S.C. Variation on a Src-like theme. Cell. 112:2003;737-740.
13. Hantschel O., Nagar B., Guettler S., Kretzschmar J., Dorey K., Kuriyan J.et al. A myristoyl/phosphotyrosine switch regulates c-Abl. Cell. 112:2003;845-857.
14. Nagar B., Bornmann W.G., Pellicena P., Schindler T., Veach D., Miller W.T.et al. Crystal structure of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62:2002;4236-4243.
15. Konopka J.B., Witte O.N. Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol. Cell Biol. 5:1985;3116-3123.
16. Pluk H., Dorey K., Superti-Furga G. Autoinhibition of c-Abl. Cell. 108:2002;247-260.
17. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W. et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell. 112:2003;859-871.
18. Van Etten R.A. c-Abl regulation: a tail of two lipids. Curr. Biol. 13:2003;R608-R610.
19. McWhirter J.R., Galasso D.L., Wang J.Y.J. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol. Cell Biol. 13:1993;7587-7595.
20. Zhao X., Ghaffari S., Lodish H., Malashkevich V.N., Kim P.S. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat. Struct. Biol. 9:2002;117-120.
21. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 13:2000;211-225.
22. McWhirter J.R., Wang J.Y.J. Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein. Oncogene. 15:1997;1625-1634.
23. Smith K.M., Van Etten R.A. Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization. J. Biol. Chem. 276:2001;24372-24379.
24. Maru Y., Witte O.N., Shibuya M. Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence. FEBS Lett. 379:1996;244-246.
25. Smith K.M., Yacobi R., Van Etten R.A. Autoinhibition of Bcr-Abl through its SH3 domain. Mol. Cell. 12:2003;27-37.
26. Million R.P., Van Etten R.A. The Grb2 binding site is required for induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase. Blood. 96:2000;664-670.
27. Azam M., Latek R.R., Daley G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 112:2003;831-843.
28. Sattler M., Griffin J.D. Molecular mechanisms of transformation by the BCR-ABL oncogene. Sem. Hematol. 40(2 Suppl. 3):2003;4-10.
29. Pendergast A.M. The Abl family kinases: mechanisms of regulation and signaling. Adv. Cancer Res. 85:2002;51-100.
30. Deininger M.W., Goldman J.M., Melo J.V. The molecular biology of chronic myeloid leukemia. Blood. 96:2000;3343-3356.
31. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341:1999;164-172.
32. Sawyers C.L. Chronic myeloid leukemia. N. Engl. J. Med. 340:1999;1330-1340.
33. Sawyers C.L., McLaughlin J., Witte O.N. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene. J. Exp. Med. 181:1995;307-313.
34. Cortez D., Reuther G., Pendergast A.M. The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 15:1997;2333-2342.
35. Raitano A.B., Halpern J.R., Hambuch T.M., Sawyers C.L. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc. Natl. Acad. Sci. USA. 92:1995;11746-11750.
36. Varticovski L., Daley G., Jackson P., Baltimore D., Cantley L. Activation of PI 3-kinase in cells expressing abl oncogene variants. Mol. Cell Biol. 11:1991;1107-1113.
37. Skorski T., Kanakaraj P., Nieborowska-Skorska M., Ratajczak M.Z., Wen S.-C., Zon G.et al. Phosphatidylinositol 3-kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 86:1995;726-736.
38. Reuther J.Y., Reuther G.W., Cortez D., Pendergast A.M., Baldwin A.S.J. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 12:1998;968-981.
39. Carlesso N., Frank D.A., Griffin J.D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl. J. Exp. Med. 183:1996;811-820.
40. BCR/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271:1996;31704-31710.
41. Shuai K., Halpern J., ten Hoeve J., Rao X., Sawyers C.L. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 13:1996;247-254.
42. Sawyers C.L., Callahan W., Witte O.N. Dominant negative myc blocks transformation by ABL oncogenes. Cell. 70:1992;901-910.
43. Dickens M., Rogers J., Cavanagh J., Raitano A., Xia Z., Halpern J.R.et al. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science. 277:1997;693-696.
44. Skorski T., Nieborowska-Skorska M., Szczylik C., Kasnakaraj P., Perrotti D., Zon G.et al. c-Raf-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res. 55:1995;2275-2278.
45. Nieborowska-Skorska M., Wasik M.A., Slupianek A., Salomoni P., Kitamura T., Calabretta B.et al. Signal transducer and activator of transcription (STAT) 5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med. 189:1999;1229-1242.
46. Wong S., McLaughlin J., Cheng D., Witte O.N. Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors. Proc. Natl. Acad. Sci. USA. 101:2003;4088-4097.
47. Kantarjian H., Sawyers C.L., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C.et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346:2002;645-652.
48. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:2002;117-125.
49. Hoover R.R., Mahon F.-X., Melo J.V., Daley G.Q. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 100:2002;1068-1071.
50. Klejman A., Rushen L., Morrione A., Slupianek A., Skorski T. Phosphatidylinositol 3-kinase inhibitors enhance the anti-leukemic effect of STI571. Oncogene. 21:2002;5868-5876.
51. Maru Y., Peters K.L., Afar D.E., Shibuya M., Witte O.N., Smithgall T.E. Tyrosine phosphorylation of BCR by FPS/FES protein-tyrosine kinase induces association of BCR with Grb-2/SOS. Mol. Cell Biol. 15:1995;835-842.
52. Pendergast A.M., Quilliam L.A., Cripe L.D., Bassing C.H., Dai Z., Li N. et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 75:1993;175-185.
53. Puil L., Liu J., Gish G., Mbamalu G., Bowtell D., Pelicci P.G.et al. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J. 13:1994;764-773.
54. Cortez D., Kadlec L., Pendergast A.M. Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis. Mol. Cell Biol. 15:1995;5531-5541.
55. Goga A., McLaughlin J., Afar D.E., Saffran D.C., Witte O.N. Alternative signals to RAS for hematopoietic transformation by the BCR-ABL oncogene. Cell. 82:1995;981-988.
56. Van Etten R.A. Models of chronic myeloid leukemia. Curr. Oncol. Rep. 3:2001;228-237.
57. Zhang X., Subrahmanyam R., Wong R., Gross A.W., Ren R. The NH2-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl. Mol. Cell Biol. 21:2001;840-853.
58. He Y., Wertheim J.A., Xu L., Miller J.P., Karnell F.G., Choi J.K.et al. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl. Blood. 99:2002;2957-2968.
59. Kardinal C., Konkol B., Lin H., Eulitz M., Schmidt E.K., Estrov Z.et al. Chronic myelogenous leukemia blast cell proliferation is inhibited by peptides that disrupt Grb2-Sos complexes. Blood. 98:2001;1773-1781.
60. Sattler M., Mohi M.G., Pride Y.B., Quinnan L.R., Malouf N.A., Podar K.et al. Essential role for Gab2 in transformation by BCR/ABL. Cancer Cell. 1:2002;479-492.
61. Gu H., Saito K., Klaman L.D., Shen J., Fleming T., Wang Y.et al. Essential role for Gab2 in the allergic response. Nature. 412:2001;186-190.
62. Sexl V., Piekorz R., Moriggl R., Rohrer J., Brown M.P., Bunting K.D.et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of STAT5. Blood. 96:2000;2277-2283.
63. Schwaller J., Parganas E., Wang D., Cain D., Aster J.C., Williams I.R.et al. et al. STAT5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol. Cell. 6:2000;693-704.